Objectives: Although several lines of evidence suggest that the overall effects of the ACTH receptor, melanocortin 2 receptor (MC2-R), mediated signal transduction on adrenocortical growth and tumorigenesis are anti-proliferative, activation of MC2-R induces mitogens like jun, fos, and myc and activates the MAPK pathway. In vivo, potential effects of endogenous ACTH on adrenal tumorigenesis can not be separated from effects of other POMC derived peptides. Methods: Murine adrenocortical tumor cells that lack MC2-R expression (Y6 pcDNA ) and Y6 cells stablely transfected with MC2-R (Y6 MC2-R ) were generated. Presence of functional MC2-R was demonstrated by RT-PCR and Western blot using an antibody for phosphorylated CREB. As a syngenic tumor model, LaHeF1/J mice simultaneously received 10 7 Y6 MC2-R and Y6 pcDNA subcutaneously, giving rise to MC2-R positive and negative tumors within the same animal. Animals were treated for 3 weeks in groups of 12 according to the following schedule: group A, control animals receiving saline injection; group B, animals receiving 5.7 ng/injection of a slow release formula of ACTH 1-24 administered i.p. three times a week (aiming at a low physiologic dose); and group C, animals receiving 57 ng/injection of ACTH 1-24 (high physiological dose). Results: Twenty days of ACTH 1-24 treatment did not significantly affect corticosterone levels, endogenous ACTH levels or adrenal and thymus weight compared with saline injection. However, ACTH 1-24 treatment of group B and C mice significantly reduced tumor weight in MC2-R positive tumors in a dose dependent manner (P ¼ 0.03), while no significant difference in tumor mass was observed in MC2-R negative tumors. PCNA and TUNEL staining, together with morphological characterization, demonstrated that these in vivo effects were due to reduced proliferation, while apoptosis and cellular hypertrophy within the tumor remained unchanged. Conclusion: MC2-R expression is associated with a less aggressive adrenal tumor phenotype and antiproliferative effects can be amplified through stimulation with physiological doses of ACTH. 153 435-444 
Introduction
ACTH is the key mediator of pituitary dependent regulation of adrenal steroidogenesis. Binding of ACTH to its cognate receptor (melanocortin 2 receptor; MC2-R) is followed by activation of several pathways, including protein kinase A (PKA) (1), PKC, MAP kinases (2) , and phospholipase C, as well as calcium channel activation (3) . In accordance with these diverse effects induced by ACTH on a molecular level, MC2-R dependent pathways have been implicated not only in the regulation of steroidogenesis but also in the regulation of adrenocortical growth, differentiation and tumorigenesis.
Adrenocortical carcinoma (ACC) is a rare but highly malignant endocrine tumor entity with overall poor long-term therapeutic options. Although recent years have witnessed considerable progress in the understanding of the molecular basis of ACC development (4) , detailed characterization of potential mediators of adrenal tumor growth is warranted. Adrenocortical tumorigenesis differs from pituitary and thyroid tumorigenesis because constitutional activation of the cAMP/PKA pathway by activating point mutations of a G-protein coupled receptor, i.e. the MC2-R, or in the a-chain of the stimulatory G-protein (Gsa, GNAS) has not been identified in benign and malign adrenocortical tumors (5 -7) . However, the McCune-Albright Syndrome, that is caused by mutations in the Gsa gene, is associated with bilateral adrenal hyperplasia and GNAS1 gene mutations could also be identified in sporadic macronodular adrenal hyperplasia (8) . On the contrary, activating mutations of the Gi2, one of the adenylate cyclase inhibitory G-proteins, has been found in some adrenocortical tumors, while these findings could not be confirmed in another series of adrenocortical tumors (7, 9) . In addition, an association between loss of heterozygosity (LOH) of the MC2-R gene, resulting in reduced expression of MC2-R mRNA with an advanced tumor stage, and a more rapid clinical course than in carcinoma patients without LOH has been demonstrated (10) (11) (12) . While these data suggest that allelic loss of the MC2-R gene in adrenocortical tumors is associated with loss of differentiation, a characteristic feature of human tumorigenesis, it is not clear whether the lack of MC2-R expression is a causative event resulting in a growth advantage and clonal expansion of a malignant cell clone.
In vivo, inactivating mutations of the MC2-R are the cause of isolated familial glucocorticoid deficiency, which is characterized by ACTH insensitivity and adrenal hypoplasia (13) . Accordingly, hypophysectomy and suppression of endogenous ACTH by glucocorticoid treatment results in decreased adrenal volume (14) . Conversely, ACTH supplementation can prevent adrenal atrophy following hypophysectomy (14) and administration of high doses of ACTH leads to hypertrophy of the adrenal cortex (15, 16), a fact that is clinically relevant in patients with congenital adrenal hyperplasia. Moreover, ACTH treatment has been demonstrated to result in increased adrenocortical cell proliferation in guinea pigs (17, 18) and rats (19). However, there is compelling evidence indicating that ACTH is not the only proopiomelanocortin (POMC)-derived peptide with effects on adrenocortical growth and a mitogenic peptide resides in the pro-g-melanocyte stimulating hormone (MSH) fraction of the POMC peptide (20, 21). Although the pro-g-MSH peptide itself does not have mitogenic potential, it has been suggested that the specific cleavage of 1-76 POMC after its secretion from the pituitary is required to release shorter fragments that exhibit potent mitogenic actions on adrenal cells (20-23).
In vitro experiments evaluating effects of ACTH on adrenocortical tumor growth have been performed since the early 1970s utilizing the murine adrenocortical tumor cell line Y1. These experiments have demonstrated the growth inhibiting effect of ACTH (24 -26) and similar results have been obtained in rat, bovine and human primary cell cultures (27 -30). However, these findings have been challenged by other in vitro experiments demonstrating ACTH induced increase in DNA synthesis and cell growth in human (31 -33) and rat (32 -34) primary adrenal cells, while biphasic effects on cellular hypertrophy and proliferation have been found under special experimental conditions (2, 34) . As further indirect evidence of growth promoting effects upon ACTH treatment, ACTH has been shown to induce potential oncogenes like jun and fos (35, 36) . Because cell culture conditions, ACTH preparations, dosage of ACTH and observational periods varied between the different studies and these experiments are poorly comparable and show limited predictive value for in vivo outcome on adrenal tumorigenesis.
Herein, we present an in vivo model for the investigation of effects of MC2-R dependent pathways on adrenal tumor growth using the Y6 cell line, which have been demonstrated to lack MC2-R expression (37) . While resistant to ACTH, Y6 cells retain signaling induced by forskolin and signal transduction pathways have been reported to be intact as transfection of an MC2-R expression led to expression of functional receptors (38) . Using this well defined and controlled tumor model, we provide evidence that physiological doses of ACTH inhibit adrenal tumor growth defining ACTH and its receptor as a possible tumor suppressor genes for adrenocortical carcinoma.
Materials and methods

Generation of MC2-R expressing Y6 cells
Cloning of the full length coding sequence of the human MC2-R gene (kind gift of R Cone) into the mammalian expression vector pcDNA 3.1 (Invitrogen, Karlsruhe, Germany) was performed via XhoI and NotI restriction sites and T4 ligase (Promega, Mannheim, Germany) and orientation and sequence was verified by direct sequencing. Murine adrenocortical Y6 cells (kind gift of B Schimmer) were transfected with the expression plasmid encoding hMC2-R (pcDNA-MC2-R) or with the empty vector (pcDNA 3.1) using ExGen reagent (Fermentas, St Leon Roth, Germany) following the instructions of the manufacturer. After 2 days in standard medium, cells were kept under selection medium containing 50 mg/ml neomycin (Geneticin, Invitrogen). Resistant cell clones were picked, expanded and diluted three times to ensure monoclonality. After dilution five clones were further maintained and one clone, with the highest MC2R expression indicated by rounding of the cells upon ACTH treatment, was selected for further experiments.
Isolation of RNA and reverse transcriptionpolymerase chain reaction (RT-PCR)
Total RNA was extracted from cells and tumor tissues, respectively, using the SV40 total RNA kit (Promega, Mannheim, Germany). One mg of RNA was reverse transcribed with Supersript II MMLV reverse transcriptase and dT18 primers (Invitrogen). One hundred ng cDNA were subjected to PCR amplification with PCR conditions as follows: 5 min at 95 8C, followed by 35 cycles with 1 min at 95 8C, 1 min at 60 8C, and 1 min at 72 8C and final extension for 5 min at 72 8C. Expression of melanocortin receptor 1 was investigated by RT-PCR with primers as published previously (39) . PCR conditions were the same as described above, but annealing temperature was 57 8C. PCR products were loaded onto a 1% agarose gel and analyzed after ethidium bromide staining.
Western blot
For determination of MC2-R function in transfected cells, Y6
MC2-R and Y6 pcDNA were grown in six well plates. Cells were incubated in 1 mM isobutylmethylxantine (IBMX) for 1 h and thereafter 10 26 M ACTH 1-24, 10 25 M forskolin or phosphate buffered saline was added. After 15 min, cells were harvested in RIPA buffer and the lysate was rocked for 2 h and heated to 958C for 10 min. 20 mg protein were loaded on a 12% SDS polyacrylamide gel and blotted to a nitrocellulose membrane. Blots were blocked in 5% non fat milk powder, and incubated overnight with an antibody for phosphorylated CREB (Sigma, Munich, Germany) or total CREB (Cell Signaling Technology, Beverly, MA, USA). Horseradish peroxidase linked anti rabbit antibody (Amersham, Freiburg, Germany) was used as a secondary antibody followed by detection with the ECL plus kit (Amersham).
Animal experiments
All experiments involving animals were performed in accordance with institutionally approved and current animal care guidelines. LaHeF1/J mice were generated as F1 hybrids from male AHe/J and female C57L/J mice (Jackson Laboratory, Bar Harbor, MN, USA), and mice with an average age of 4.5 months and with an weight of 26 -34 g were used for the study. All animals were maintained under standard conditions of temperature (22 8C) and lighting (12L: 12D) and food and water was given ad libidum. 10 7 cells Y6 MC2-R and Y6 pcDNA , respectively, were injected subcutaneously to the right and left side of the neck on day 0. ACTH 1-24 in a slow release formula (Synacthen depot, Novartis, Erlangen, Germany) was injected at two dosages (5.7 and 57 ng/injection) i.p. on days 1, 2 and 3 and then three times a week, corresponding to a low and high physiological dosage, respectively. Control mice received i.p. saline injections accordingly. 12 mice per group were studied. On day 20, mice were euthanized between 0800 h and 1100 h using isofluran and blood was drawn by cardiac puncture within 60 s of initial handling. Tumors were dissected from adjacent tissue, Figure 1 (A) Effects of exogenous ACTH 1-24 treatment on corticosterone levels, (B) endogenous plasma ACTH levels, (C) adrenal weight and (D) thymus weight, suggesting lack of significant changes on the assessed markers. On day 20, 48h after the last injection, the tumor bearing mice were euthanized and blood was drawn for measurement of corticosterone and ACTH. Adrenals and thymus glands were dissected and weight was determined.
weighed and snap-frozen in liquid nitrogen or fixed in 4% paraformaldehyde. As in vivo controls of ACTH bioactivity, adrenal and thymus weight were determined after preparation of the organs.
Hormone measurements
Plasma ACTH concentration, as depicted in Fig. 1 , was measured using a commercial two site assay (Nichols Advantage, ACTH Assay, Nichols Institute Diagnostics, San Clemente, CA, USA) which has a cross reactivity of approximately 1% with synthetic ACTH 1-24. In addition, for dose finding studies, total ACTH plasma levels were measured with an assay that detects murine endogenous and synthetic ACTH 1 -24 with a specifity of 100% (DSL-2300, Webster, TX, USA). Plasma corticosterone was determined by radioimmunoassay (RIA) using an 125 I RIA kit according to the manufacturer's protocols (ICN Biomedical, Costa Mesa, CA, USA).
Cell counts
Hematoxylin -eosin stained tumor sections were examined with a standard light microscope using 400 £ magnification. Cell nuclei of three independent tumor sections from three different animals per group were counted under standardized conditions. Cell counts were expressed as cell number/high power field (HPF).
Immunohistochemistry
For PCNA immunohistochemistry, paraffin embedded tumor sections were rehydrated and incubated overnight with a rabbit polyclonal antibody (Santa-Cruz Biotechnology, Santa Cruz, CA, USA) in a dilution of 1:100 in blocking buffer containing 3% bovine serum albumin (BioRad, Munich, Germany), 5% goat serum (DAKO, Hamburg, Germany), and 0.5% Tween 20. Bound antibody was detected by horseradish peroxidase linked anti-rabbit-IgG (Amersham) and staining with DAB (Sigma) after blockage of endogenous peroxidase with 0.6 hydrogen peroxide in methanol. Sections treated accordingly, but without incubation with primary antibody served as a negative control. Sections were lightly counter-stained with hematoxylin and percentage of positive cells was determined counting 5 HPFs per section.
Detection of apoptotic cells in paraffin embedded tumor sections was performed using the dead-end TUNEL assay (Promega) following the instructions of the manufacturer.
Statistical analysis
All results are expressed as mean^S.E.M. Statistical comparisons were analyzed by ANOVA and Fisher's protective least significant difference test using Stat View (SAS Institute, Cary, NC, USA). Statistical significance was defined as P , 0.05 and is indicated as a asterisk ( * ) or cross ( †) in the figures.
Results
Transfection of hMC2-R expression vector reconstitutes functional MC2-R in Y6 cells
Transfection of Y6 cells with a human MC2-R encoding cDNA resulted in stable expression of hMC2-R mRNA in Y6 MC2-R , while expression of endogenous mMC2-R was excluded in both Y6
MC2-R and Y6 pcDNA by RT-PCR ( Fig. 2A) . Functionality of the transfected receptor was demonstrated by stimulation of the cells with ACTH 1-24 and subsequent detection of phosphorylated CREB (pCREB) by western blotting. As expected, increase in pCREB protein levels was induced upon stimulation with ACTH in Y6 MC2-R , while pCREB remained undetectable in ACTH treated Y6 pcDNA cells (Fig. 2B) . As a positive control, increase in intracellular cAMP levels by forskolin treatment demonstrated increase in CREB phosphorylation.
Applied ACTH treatment regimes do not result in overt hypercortisolism
During the observation period of 20 days, ACTH 1-24 was injected intra-peritoneally with two different dosages, while control animals received saline injections at the same intervals. While 12 animals were assigned to every group, one mouse receiving 5.7 ng ACTH 1-24 showed signs of suffering and was euthanized before completion of the study. Preliminary dose finding studies were performed to titrate synacthen doses that would result in low or high physiological ACTH levels. Plasma ACTH levels, which were determined with an assay that detects both endogenous and 1-24 ACTH, increased over baseline (180 pg/ml) over the 48 h observation period after injection of 57 ng ACTH1-24 (high physiological dose) with a peak value around 24 h after injection (376^17 pg/ml) and substantial decrease thereafter (79^5 pg/ml).
In accordance with these results, ACTH treatment regimens aiming at low and high physiological doses did not significantly affect corticosterone and ACTH levels measured 48 h after the last injection (5.7 ng, 208.8^24.3 ng/ml (P ¼ 0.61); 57 ng, 204.22 6.2 ng/ml (P ¼ 0.69) vs 191.0^18.2 ng/ml in saline treated animals and 5.7 ng, 191.0^22.5 ng/ml (P ¼ 0.98); 57 ng, 230.6^28.1 ng/ml (P ¼ 0.35) vs 191.9^34.5 ng/ml in saline treated animals, respectively; Figs 1A and B). To further evaluate the possible long term biological effects of ACTH 1-24 treatment regimens, adrenal weight (as a measure of ACTH induced adrenal hypertrophy) and thymus weight (as a measure of glucocorticoid excess) were monitored. In accordance with the comparable hormone levels between the groups, ACTH 1-24 treatment had no significant effect on adrenal weights (5.7 ng, 8.6^0.5 mg (P ¼ 0.45); 57 ng, 8.0^0.8 mg (P ¼ 0.67) vs 7.3^0.9 mg in saline treated animals; Fig. 1C ) or thymus weights (5.7 ng, 36^3 mg (P ¼ 0.9); 57 ng, 34^3 mg (P ¼ 0.8) vs 35^8 mg in saline treated animals; Fig. 1D ). Taken together, these results indicate that the amount of injected ACTH 1-24, which was calculated to aim at low and high physiological levels, did not induce significant perturbation of the HPA axis or overt hypercortisolism.
ACTH treatment results in lower weight of MC2-R expressing tumors
Subcutaneous injection of MC2-R positive and negative cells into the neck of LaHeF1/J mice resulted in palpable tumors within 20 days (Fig. 3A) . Overall, MC2-R expression in Y6 derived tumors was associated with a lower tumor weight (saline, 1242^160 mg (Y6 MC2-R ) vs 1692^219 mg (Y6 pcDNA ) (P ¼ 0.09); 5.7 ng ACTH 1-24, 748^147 mg vs 1416^147 mg, (P ¼ 0.02); 57 ng ACTH 1-24, 657^140 mg vs 1398^275 mg (P ¼ 0.007); Fig. 3B ). In addition, ACTH 1-24 treatment further reduced tumor weight in MC2-R positive tumors (5.7 ng ACTH 1-24, 748^147 mg (P ¼ 0.07); 57 ng ACTH 1-24, 657^140 mg (P ¼ 0.03) vs saline, 1242^160 mg) while weight of MC2-R negative tumors was not significantly affected by ACTH treatment (5.7 ng ACTH 1-24, 1416^147 mg (P ¼ 0.31); 57 ng ACTH 1-24, 1398^275 mg, P ¼ 0.27 vs saline, 1692^219 mg; Fig. 3B ). Taken together, these results demonstrate an association with a less aggressive phenotype in adrenal tumors expressing MC2-R in comparison to MC2-R negative tumors which can be further amplified by exogenous ACTH treatment.
ACTH treatment inhibits proliferation in MC2-R expressing tumors
Since ACTH 1-24 induced reduction in tumor weight could be due to suppression of proliferation, induction of apoptosis or reduction of cell volume, PCNA immunohistochemistry, TUNEL staining and cell counts per HPF were analyzed in the different tumor samples. While the number of PCNA positive cells was not affected in MC2R negative tumors (5.7 ng ACTH 1-24, 56.5^2.5% (P ¼ 0.16); 57 ng ACTH 1-24, 59.3^2.3% (P ¼ 0.61) vs saline, 58.0^2.1%; Fig. 4 A-E), PCNA expression was significantly reduced with increasing doses of ACTH in MC2-R expressing tumors (5.7 ng ACTH 1-24, 51.2^3.3% (P ¼ 0.56); 57 ng ACTH 1-24, 39.6^1.4% (P , 0.02) vs saline, 60.8^2.1%; Fig. 4A-E Fig. 4K-O) . Taken together, these results indicate that the observed effects of ACTH on tumor growth are mainly mediated by suppression of cellular proliferation.
Transfected Y6 derived tumors retain MC2-R expression but lose MC1-R expression
As regain of endogenous MC2-R expression in Y6 cells after passage in mice has been reported (37) and to assess possible changes in the expression pattern in the tumor samples that would affect ACTH responsiveness, expression of MC2-R and MSH receptor (melanocortin 1 receptor (MC1-R)) was evaluated in a subset of tumors. Analysis of the tumors for human and mouse MC2-R expression excluded loss of human MC2R expression after passage in the animals, whereas murine MC2-R mRNA expression remained undetectable (Fig. 5A ) in all tumor samples studied. In addition, although the parent Y6 cell lines used in our experiments showed expression of MC1-R, this expression was lost in both the MC2-R positive and MC2-R negative tumor 
Discussion
While the mechanisms of steroid hormone production have been characterized in quite some detail, little is known about the regulatory factors that are responsible for the proliferation and differentiation of steroidogenic cells. As for the adrenal cortex, there is an increasing body of evidence suggesting that ACTH, in addition to its role in the regulation of steroidogenesis, has an impact on adrenal differentiation and growth also in the context of adrenal tumorigenesis. Accordingly, adrenocortical carcinoma frequently lack MC2-R expression, a phenotype which is associated with a more aggressive tumor growth and poor prognosis (4, 11, 12, 40) . To date, it is not clear, however, whether this loss of MC2-R expression plays a causative role in adrenal tumorigenesis or is the mere result of the development of advanced tumor stages with an overall less differentiated phenotype. Herein, we present evidence that MC2-R expression is, in fact, closely related to a less aggressive adrenal tumor phenotype which can be amplified by ACTH treatment. We furthermore demonstrate that activation of MC2-R dependent pathways results in suppression of proliferation, while apoptosis and cellular hypertrophy are not affected by ACTH treatment in this tumor model. Although the decrease in the proliferation marker PCNA associated with the presence of MC2-R was modest, these changes were sufficient to cause significant growth retardation with lower tumor weight in comparison to tumors lacking MC2-R expression.
Functional in vitro expression of the MC2-R has been difficult to achieve, because of the presence of MC1-R with background activity after stimulation with ACTH (41, 42) or because of failed retained receptor protein in the endoplasmatic reticulum (43) most likely due to the lack of the recent cloned melanocortin 2 receptor accessory protein (MRAP) (44) . Y6 cells which have been derived from the Y1 adrenocortical tumor cell line as ACTH resistant cell clones have been characterized by defective expression of wild type MC2-R, despite a normal DNA sequence encoding that receptor while retaining signaling properties induced by forskolin (37) . Accordingly, these cells have successfully been utilized in transfection models to demonstrate the characteristics of mutant MC2-R in vitro that were identified in patients with familial glucocorticoid deficiency (45) . Although the cellular phenotype of Y6 cells is linked to a polymorphism of the transcription factor SF-1, the underlying molecular defect that affects SF-1 function has not been elucidated in detail (46) . As we demonstrate, MC2-R expression can be maintained after stable transfection even after passage in vivo, and restoration of MC2-R expression has a significant impact on tumor physiology. In contrast to normal adrenocortical cells, ACTH has no significant effect on cellular hypertrophy in this tumor model, a feature that might be associated with the overall low steroidogenic properties of this cell line (47) .
It has to be noted that ACTH treatment did also affect growth of MC2-R negative tumors, although to a lesser extent than MC2-R expressing tumors and without reaching statistical significance. In mice, ACTH has low affinity to the MSH receptor, MC1-R (48, 49) , therefore, we hypothesized that higher doses of ACTH might activate MC1-R dependent pathways and may affect the tumor phenotype independently of MC2-R expression. Thus, we investigated the Y6 cell lines and the resulting tumors for MC1R expression. Interestingly, although MC1-R expression could be demonstrated in our strains of the parental Y6 cell lines, its expression was lost following the passage in the animals. Tumors are prone to change their biological phenotype through chromosomal instability, increased mutation rate and transcriptional regulation that result in the growth advantage of certain tumor clones. In this context, loss of MC1-R expression in the course of tumor development might be interpreted as loss of differentiation in these tumor clones. However, ACTH dependent effects on adrenal tumor growth in this model are not to be explained by activation of MC1-R dependent pathways.
As in all complex in vivo models, direct treatment effects have to be differentiated from possible indirect effects that might have impact on the overall phenotype. Such possible indirect effects that could affect adrenal tumor growth include alteration of the endogenous hypothalamus-pituitary-adrenal (HPA) axis by exogenous ACTH treatment. Higher doses of ACTH such as those given in our study increase adrenal steroidogenesis and it cannot be excluded that elevated glucocorticoid levels might directly affect adrenocortical tumor growth. In addition, and in accordance with the hypothesis that the pro-g-MSH fraction of POMC harbors a peptide with mitogenic properties to the adrenal cortex (23, 50), the glucocorticoid induced suppression of endogenous POMC might also have affected adrenal tumor growth. To circumvent these disturbances, we chose ACTH doses that did not cause overt hypercortisolism as demonstrated by the lack of significant changes in corticosterone and endogenous ACTH levels at the end of the study. As more subtle indicators of long term ACTH bioactivity, adrenal weights as markers of ACTH induced adrenal hypertrophy and thymus weights as markers of glucocorticoid action on lymphatic tissue were assessed and did not show significant differences between the treatment groups. However, time course experiments after the injection of a slow release form of ACTH 1-24 disrupts the physiological diurnal rhythm of HPA axis activity with intermittently elevated blood levels of total ACTH. In this respect, it could be argued that the small decrease in MC2-R negative tumor cells upon ACTH treatment might be due to lower levels of endogenous N-POMC peptides levels, thus adding another facet to mechanisms of ACTH dependent suppression of adrenal tumor growth.
Taken together, we demonstrate a growth inhibiting effect of ACTH 1-24 in an in vivo adrenocortical tumor model using high physiological doses of ACTH. We present evidence that this effect is most likely independent of pituitary function and corticosterone levels, suggesting direct effects of ACTH treatment on adrenocortical tumor growth. Novel treatment options for patients with adrenocortical carcinoma are urgently needed. Based on our data, it seems reasonable to speculate about possible clinical applications of antiproliferative actions of ACTH. For example, in patients with adrenocortical carcinoma, combined treatment of low doses of ACTH with differentiation inducing agents such as peroxisome proliferator activated receptor (PPAR).g agonists that antagonize loss of MC2-R expression in adrenocortical carcinoma (51) might be considered a compelling future concept. 
